What Our Community Has Accomplished
When our neighbors in Southeast Texas step up to participate in clinical research, the results reach patients around the world. These are the stories of what our community has helped make possible.
2
FDA-Approved Drugs
300+
Clinical Trials Managed
Top 5
Global Site Rankings
20+
Years Serving Southeast Texas
FDA-Approved Breakthroughs
Our community's participation directly contributed to treatments now helping patients nationwide.
Kisunla (Donanemab) — Alzheimer's Treatment
When our Southeast Texas neighbors volunteered for the TRAILBLAZER-ALZ 2 trial, they became part of something historic. Their participation — among the top 5 of any site worldwide — helped bring Kisunla to FDA approval. Today, this treatment is slowing cognitive decline for Alzheimer's patients across the country.
Top 5
Site Worldwide
35%
Slower Decline
2024
FDA Approved
"Because our community stepped up, patients everywhere now have access to a treatment that wasn't available before."
Abrysvo — Protecting Babies from RSV
RSV is the leading cause of infant hospitalization in the United States. When pregnant mothers in our community volunteered for the MATISSE trial, they helped prove that a single vaccine during pregnancy could protect newborns from birth. Their contribution was among the top 3 globally out of 464 sites — and it led to FDA approval of Abrysvo, the first-ever maternal RSV vaccine.
Top 3
of 464 Sites
82%
Efficacy at 90 Days
2023
FDA Approved
"We're proud our community stepped up. Because they did, babies across America are now protected from RSV from the moment they're born."
What's Next — Currently Enrolling
Our community continues to lead. These are the cutting-edge studies our neighbors are participating in right now.
Roche BrainShuttle™ — Trontinemab
Southeast Texas participants are now part of the Phase 3 trial of trontinemab, powered by Roche's revolutionary BrainShuttle™ technology. This breakthrough transports medicine directly across the blood-brain barrier — and our neighbors are among the first in the world to access it.
Why This Matters:
- 91% of patients became amyloid-negative in early trials
- Delivers treatment across the blood-brain barrier via simple IV infusion
- Could become the next generation of Alzheimer's therapy
Merck Anti-Tau (MK-2214) — Targeting the Other Half of Alzheimer's
Most Alzheimer's drugs target amyloid plaques. But tau tangles — the toxic protein threads that spread through the brain — are more closely linked to memory loss and cognitive decline. Our community now has the opportunity to participate in Merck's MK-2214 trial, an anti-tau antibody designed to stop tau from spreading.
Why Tau Matters:
- Tau tangles correlate more closely with dementia severity than amyloid plaques
- MK-2214 received FDA Fast Track designation in 2025
- Targeting tau alongside amyloid could be the key to truly stopping Alzheimer's
Pediatric Weight Management — GLP-1 Study
GLP-1 medications have transformed adult weight management. Now, families in Southeast Texas will have access to a pediatric GLP-1 clinical trial — bringing the next generation of weight management science to our community's children and adolescents.
What This Means for Families:
- Access to cutting-edge weight management medication at no cost
- Expert medical monitoring throughout the study
- Helping shape the future of pediatric obesity treatment
GAP-Net Member Site
Gadolin Research is a proud member of GAP-Net, the Global Alzheimer's Platform Foundation's invitation-only network of best-in-class clinical research sites. GAP-Net includes over 100 leading private and academic research centers across North America and Europe — including institutions like Mayo Clinic, Stanford, Baylor College of Medicine, and Banner Alzheimer's Institute.
As a GAP-Net site, Gadolin participates in the collaborative effort to accelerate neurodegenerative research, improve clinical trial efficiency, and bring innovative treatments to patients faster. GAP-Net sites achieve up to 30% faster study start-up and 45% improvement in screening rates compared to non-network sites.
Be Part of the Next Breakthrough
Our community has already helped bring two FDA-approved treatments to market. Join your neighbors in advancing medicine for everyone.